Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh(BR:D2NL34)
R$21.64+0.10 (+0.46%)
BR:D2NL34
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh earnings date
R$21.64
At close:+0.10 (+0.46%)
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh (D2NL34) Q2 2024 Earnings Report
BR:D2NL34 Q2 2024 EPS Results
- Actual EPS
- BRL 0.00
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- BRL 0.00
BR:D2NL34 Q2 2024 Revenue Results
- Actual Revenue
- BRL 0
- Expected Revenue
- ―
- Beat/Miss
- ―
- YoY Revenue Growth
- -100.00%
Earnings Announcement Details
- Quarter
- Q2 2024
- Date
- 08/01/2024
- Time
- Before Open
- Conference Call
- Thursday, August 1, 2024
BR:D2NL34 Upcoming Earnings
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh's next earnings date is estimated for March 1, 2027, based on past reporting schedules.
Q2 2024 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2024 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2024 Earnings Call Summary
No earnings call summary is available for this earnings event.
BR:D2NL34 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 01, 2027 | 2026 (Q4) | ―- | 0 | ― | ― |
| Nov 03, 2026 | 2026 (Q3) | ―0.00 | 0 | 100.00% (+0.00) | |
| Aug 06, 2026 | 2026 (Q2) | ―-0.00 | 0 | 0.00% (+0.00) | |
| May 07, 2026 | 2026 (Q1) | ―-0.00 | 0 | 0.00% (+0.00) | |
| Feb 26, 2026 | 2025 (Q4) | ―-0.00 | 0 | 0.00% (+0.00) | |
| Nov 06, 2025 | 2025 (Q3) | ―-0.00 | 0 | 0.00% (+0.00) | |
| Aug 11, 2025 | 2025 (Q2) | ―-0.00 | 0 | 0.00% (+0.00) | |
| May 06, 2025 | 2025 (Q1) | ―-0.00 | 0 | 0.00% (+0.00) | |
| Feb 27, 2025 | 2024 (Q4) | ―-0.00 | 0 | 0.00% (+0.00) | |
| Nov 06, 2024 | 2024 (Q3) | ―-0.00 | 0 | 0.00% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed

